Blood 2022, in Sydney was a great meeting for the MRDR with seven presentations of MRDR and M1000 biobank data. The presentations covered diverse areas in myeloma research including biomarkers for high risk of progression in smouldering myeloma, treatment in relapsed and newly diagnosed myeloma, immunoglobulin use, disease staging, and modelling the impact of treatments.
Thanks to patients, research staff and clinicians at MRDR sites for your contribution to this research.